In an obese 40‑week pregnant woman undergoing trial of labor after cesarean with planned oxytocin augmentation, what is the appropriate tool to assess fetal size?

Obstetric Ultrasound for Estimated Fetal Weight

The appropriate tool to assess fetal size in this clinical scenario is obstetric ultrasound with estimated fetal weight (EFW) calculation using population-based references such as Hadlock. 1

Rationale for Ultrasound Assessment

In an obese woman at 40 weeks undergoing TOLAC with anticipated oxytocin augmentation, accurate fetal size assessment is critical for several reasons:

• Obesity increases risk of cephalopelvic disproportion and failed TOLAC, making fetal size assessment particularly important 2
• Oxytocin FDA labeling specifically contraindicates use in borderline cephalopelvic disproportion except in unusual circumstances 2
• The combination of obesity, TOLAC, and oxytocin augmentation creates a higher-risk scenario where fetal size directly impacts decision-making

Specific Ultrasound Parameters to Obtain

While performing the ultrasound for fetal size assessment, obtain:

• Estimated fetal weight (EFW) using standard biometric parameters
• Abdominal circumference (AC) 1
• Head circumference (HC) - independently associated with TOLAC success 3
• Fetal head circumference to maternal subpubic angle ratio (HC/SPA) if available, as HC/SPA ≥3.30 significantly increases risk of operative delivery 4

Clinical Application

The ultrasound findings should be interpreted as follows:

• Use Hadlock or other population-based growth references for percentile determination 1
• Smaller fetal head circumference is associated with higher TOLAC success rates (mean 330mm vs 333mm in failures) 3
• In obese women specifically, fetal biometry combined with maternal pelvic measurements provides superior prediction of delivery mode compared to clinical examination alone 4

Critical Safety Considerations

Given the oxytocin augmentation plan:

• Borderline cephalopelvic disproportion is a relative contraindication to oxytocin per FDA labeling 2
• If EFW suggests macrosomia (>4000-4500g depending on maternal diabetes status), carefully weigh risks versus benefits of proceeding with TOLAC and oxytocin
• Continuous fetal monitoring is mandatory once oxytocin is initiated 2
• Women with obesity may require approximately twice the oxytocin dose for adequate uterine response 5

Common Pitfalls to Avoid

• Do not rely on clinical estimation alone - ultrasound is more accurate, particularly in obese patients where palpation is limited
• Do not ignore the head circumference measurement - focusing only on EFW misses important predictive information for TOLAC success 3
• Do not proceed with oxytocin if ultrasound reveals suspected macrosomia with borderline pelimetry without explicit informed consent and careful risk-benefit discussion 2